Widely read:
Shares of Divi's Laboratories surged 5 per cent to close at Rs 5,889 on February 3, 2025, after the company reported a robust set of numbers for Q3 FY25. The pharmaceutical major posted a revenue of Rs 2,319 crore, reflecting a 25 per cent jump from Rs 1,855 crore in the same quarter last year. Net profit also saw a strong uptick, rising 65 per cent year-on-year to Rs 589 crore.
Numbers at a glance
| Particulars | Q3 FY25 | Q3 FY24 | Change (% YoY) |
|---|---|---|---|
| Revenue (Rs cr) | 2,319 | 1,855 | 25.0 |
| Operating profit (Rs cr) | 644 | 394 | 63.5 |
| Operating margin (%) | 27.8 | 21.2 | 6.5 |
| Profit after tax (Rs cr) | 589 | 358 | 64.5 |
About Divi's Labs
Established in 1990, Divi's Laboratories is a leading manufacturer of Active Pharmaceutical Ingredients (APIs), intermediates, and nutraceutical ingredients. The company operates globally with a strong presence in regulated markets like the US and Europe. Known for its focus on research-driven innovation and cost-efficient production, Divi's has consistently expanded its manufacturing capabilities. The recent commencement of operations at its Unit-III facility in Kakinada underscores its commitment to scaling up capacity and strengthening its position in the API industry.
Also read: Why are SBI Life, HDFC Life and other private insurers in the red?
Disclaimer: This content is for information only and should not be considered investment advice or a recommendation.
For grievances: [email protected]
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
